Early-stage investor Karna D Shinde has invested in neuro42 over multiple rounds in the last few years
In a recent announcement, neuro42, a medical technology company pioneering portable MRI, robot and AI technologies has secured undisclosed investments from investor, Karna D Shinde. This is Karna’s third round of investment in the company.
neuro42 recently received USFDA clearance for its innovative diagnostic MRI product. The 510(k) clearance, received in February 2024, marks a significant milestone for neuro42 and sets the stage for the commercialisation of its cutting-edge diagnostic MRI machine later this year.
neuro42’s portable MRI is designed to specialise in imaging the brain and head, with a key focus on MR-guided interventions. One of the primary drivers of innovation at neuro42 is its ability to amplify the capabilities of neurosurgeons, particularly in complex and time-sensitive procedures such as the treatment of brain tumors and epilepsy.
“The diagnostic and interventional capabilities of neuro42’s MRI have the potential to transform the way challenging brain tumor cases are approached and treated,” stated Karna D Shinde, Investor and Strategic Advisor.
“We are thrilled to announce the FDA clearance of our bedside MRI product. Our team has been focused on making a difference in patient care, and now we can finally arm healthcare providers with a valuable tool to improve accessibility to neuroimaging.” said Abhita Batra, Founder and Chief Strategy Officer of neuro42.
The company prepares to launch its product later this year.
neuro42 MRI is receiving positive feedback and has generated significant interest from healthcare facilities in multiple Indian states like Telangana, Maharashtra, and Karnataka. The fact that neuro42 has obtained USFDA clearance is indeed a significant milestone for the company.